Lumida
/MASS
⌘K
908 Devices Inc

908 Devices Inc

MASS
$7.35USD↓-0.81%-0.06 today

MARKET CAP

301.5M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$7 – $7

52W RANGE

$5
$9

AI Summary

Stalk
StalkMedium

We maintain a bullish medium-term bias in this speculative stock amid a Stage 2 advance; however, near-term execution is deferred due to overextension and overbought conditions at recent highs. We await a pullback into the rising short-term EMAs for a more asymmetric entry zone. The long-term uptrend remains intact, supported by sequential higher highs and lows and rising major moving averages.

  • ↑Q1 '26 revenue +14% YoY to $13.4M; state/local ~50%
  • ↑NearLab acquisition adds ~$2.5M revenue in 2026 and expands product line
  • ↓Q1 2026 net loss widened to $12M from $9.8M a year ago
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

908 Devices Inc. (NASDAQ: MASS) specializes in innovative handheld analytical instruments for various critical sectors such as law enforcement, healthcare, and public safety. Within the growing domain of chemical analysis technologies, the company positions itself effectively to address urgent public health challenges, particularly in narcotics detection. With a focus on excellence in mass spectrometry and infrared spectroscopy solutions, 908 Devices is capitalizing on increasing demand driven by heightened concerns over drug crises and advancing defense market needs.

Bull says

  • ↑Q1 '26 revenue +14% YoY to $13.4M; state/local ~50%
  • ↑NearLab acquisition adds ~$2.5M revenue in 2026 and expands product line
  • ↑End-of-Q1 cash of $111.7M with zero debt supports growth investments
  • ↑Full-year guide $67–70M revenue implies 19–25% YoY growth
  • ↑Gross margin rose to 51% from 47% YoY on recurring revenues
  • ↑Opioid crisis and federal funding surge propel handheld detector demand

Bear says

  • ↓Q1 2026 net loss widened to $12M from $9.8M a year ago
  • ↓Adjusted EBITDA loss remains mid-single-digit millions despite cost cuts
  • ↓One-third of revenue from government contracts exposes funding risk
  • ↓11.3% short interest signals strong market skepticism
  • ↓Negative earnings yield and weak profitability highlight inefficient margins
  • ↓NearLab integration risks could challenge operational execution

Investment themes with MASS

Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR
Others↑ +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-10-2026bullish

Transcript signals

Bull points

  • Total revenue was $13.4 million for the first quarter 2026, increasing 14% from $11.8 million in the prior year period.
  • Handheld product and service revenue was $12.8 million for the first quarter 2026, up 16% from $11 million for the first quarter 2025.
  • we now expect revenue to be in the range of 67 to 70M, representing growth of 19 to 25% over full year 2025.

Bear points

  • Recurring revenue, which consists of consumables, accessories, software, and service revenue, represented 30% of total revenues this quarter and was $4 million, a 7% decrease over the prior year period, primarily related to the expected reduction in mass spec service revenue.
  • Net loss from continuing operations for the first quarter of 2026 was 12 million compared to a net loss of 9.8 million in the prior year period.
Read full transcript analysis ›